New classification for identifying HR myeloma based on cytogenetic abnormalities
Dr Sankaranarayanan of the International Agency for Research on Cancer (IARC) discusses the approach of using low technology methods for the prevention and detection of cancer in the African setting.
This filming was supported by an unrestricted grant from Pfizer Oncology.
New classification for identifying HR myeloma based on cytogenetic abnormalities
Tele-mentoring: Impact of project ECHO
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Choosing the right patients for transplant
Choosing Wisely in endometrial & cervix cancers: Medical therapy
Cancer mutation prediction using artificial intelligence
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Understanding patient factors and barriers in oncology treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications